2023
DOI: 10.1126/sciadv.adi2687
|View full text |Cite
|
Sign up to set email alerts
|

PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities

Nina Đukić,
Øyvind Strømland,
Jonas Damgaard Elsborg
et al.

Abstract: PARP14 is a mono–ADP-ribosyl transferase involved in the control of immunity, transcription, and DNA replication stress management. However, little is known about the ADP-ribosylation activity of PARP14, including its substrate specificity or how PARP14-dependent ADP-ribosylation is reversed. We show that PARP14 is a dual-function enzyme with both ADP-ribosyl transferase and hydrolase activity acting on both protein and nucleic acid substrates. In particular, we show that the PARP14 macrodomain 1 is an active … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

5
52
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 28 publications
(58 citation statements)
references
References 93 publications
5
52
1
Order By: Relevance
“…Compounds that target the NAD+ binding pocket with subsequent ART activity inhibition, e.g., 14,29 , or that target the NAD+ binding pocket with subsequent Parp14 proteolysis (proteolysis targeting chimera) 30 have been reported. Also, one line of research has focused on compounds that target the Parp14 macrodomains, e.g., [31][32][33] , involved in the binding of Parp14 to ADP-ribose conjugates and removal of them 5,6 . Therefore, pharmaceutical perturbation of Parp14 functions is being explored at multiple levels from the overall Parp14 amount to its ART activity, and from Parp14-mediated ADP-ribose-dependent molecular scaffolding to reversal of ADP-ribosylation dependent cell signalling events.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Compounds that target the NAD+ binding pocket with subsequent ART activity inhibition, e.g., 14,29 , or that target the NAD+ binding pocket with subsequent Parp14 proteolysis (proteolysis targeting chimera) 30 have been reported. Also, one line of research has focused on compounds that target the Parp14 macrodomains, e.g., [31][32][33] , involved in the binding of Parp14 to ADP-ribose conjugates and removal of them 5,6 . Therefore, pharmaceutical perturbation of Parp14 functions is being explored at multiple levels from the overall Parp14 amount to its ART activity, and from Parp14-mediated ADP-ribose-dependent molecular scaffolding to reversal of ADP-ribosylation dependent cell signalling events.…”
Section: Discussionmentioning
confidence: 99%
“…The pcDNA3.1-Flag-Parp14 plasmid to express human Parp14 (N-terminal Flag-tag) has previously been described 38 . HEK293T cells grown in DMEM (21969035, Thermo Fisher) + 10% FBS (S181B-500, Biowest) + 2mM L-glutamine (25030081, Gibco) + 25mM HEPES (15630-056, Gibco) were seeded in 10 mL volumes in 10 cm dishes (1×10 6 cells / 10 cm dish) in the late afternoon. The next morning fresh media was exchanged and the cells were transfected with 4 µg of plasmid DNA using calcium-phosphate transfection reagents (prepared in-house).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…The subfamily of macrodomain containing PARP enzymes (PARP9, PARP14 and PARP15) was originally identified as B-aggressive lymphoma (BAL) proteins 1-3 [11]. PARP9 and PARP14 contain a macrodomain with ADP-ribosyl glycohydrolase activity [12][13][14] as well as one and two ADP-ribosyl binding macrodomains, respectively [15][16][17]. PARP15, the third member of the subfamily, originated by partial duplication of the structurally more complex PARP14 early during mammalian evolution.…”
Section: Introductionmentioning
confidence: 99%
“…PARP14 is a multidomain protein and its domain architecture was recently re-analyzed using Alphafold2 (10). This analysis determined that PARP14 contains 3 RRM domains, 7 full KH domains and 1 split KH domain that are suspected to bind to nucleic acids, 3 macrodomains (MDs) one of which has an ADP-ribose hydrolase activity (MD1) (10–12), a WWE domain that is suspected to bind ADP-ribose subunits, and the ART catalytic domain (10).…”
Section: Introductionmentioning
confidence: 99%